Evidence map›Paper›PMID 30203051›Full record

ArticleCardiovascular research2019

Role of type 2A phosphatase regulatory subunit B56α in regulating cardiac responses to β-adrenergic stimulation in vivo.

Sarah-Lena Puhl, Kate L Weeks, Alican Güran, Antonella Ranieri, Peter Boknik, Uwe Kirchhefer, Frank U Müller, Metin Avkiran

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Sarah-Lena PuhlSchool of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, Westminster Bridge Road, London, UK.
Kate L WeeksSchool of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, Westminster Bridge Road, London, UK.
Alican GüranSchool of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, Westminster Bridge Road, London, UK.
Antonella RanieriSchool of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, Westminster Bridge Road, London, UK.
Peter BoknikInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Domagkstrasse 12, D-48149 Münster, Germany.
Uwe KirchheferInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Domagkstrasse 12, D-48149 Münster, Germany.
Frank U MüllerInstitut für Pharmakologie und Toxikologie, Universitätsklinikum Münster, Domagkstrasse 12, D-48149 Münster, Germany.
Metin AvkiranSchool of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, Westminster Bridge Road, London, UK.
University Hospital Münster · DEKing's College London · GBBaker Heart and Diabetes Institute · AUBritish Heart Foundation · GBSt Thomas' Hospital · GB

Funding

British Heart Foundation PG/12/48/29638British Heart Foundation RE/13/2/30182
6 · The paper itself

Abstract

aimsB56α is a protein phosphatase 2A (PP2A) regulatory subunit that is highly expressed in the heart. We previously reported that cardiomyocyte B56α localizes to myofilaments under resting conditions and translocates to the cytosol in response to acute β-adrenergic receptor (β-AR) stimulation. Given the importance of reversible protein phosphorylation in modulating cardiac function during sympathetic stimulation, we hypothesized that loss of B56α in mice with targeted disruption of the gene encoding B56α (Ppp2r5a) would impact on cardiac responses to β-AR stimulation in vivo. METHODS AND

resultsCardiac phenotype of mice heterozygous (HET) or homozygous (HOM) for the disrupted Ppp2r5a allele and wild type (WT) littermates was characterized under basal conditions and following acute β-AR stimulation with dobutamine (DOB; 0.75 mg/kg i.p.) or sustained β-AR stimulation by 2-week infusion of isoproterenol (ISO; 30 mg/kg/day s.c.). Left ventricular (LV) wall thicknesses, chamber dimensions and function were assessed by echocardiography, and heart tissue collected for gravimetric, histological, and biochemical analyses. Western blot analysis revealed partial and complete loss of B56α protein in hearts from HET and HOM mice, respectively, and no changes in the expression of other PP2A regulatory, catalytic or scaffolding subunits. PP2A catalytic activity was reduced in hearts of both HET and HOM mice. There were no differences in the basal cardiac phenotype between genotypes. Acute DOB stimulation induced the expected inotropic response in WT and HET mice, which was attenuated in HOM mice. In contrast, DOB-induced increases in heart rate were unaffected by B56α deficiency. In WT mice, ISO infusion increased LV wall thicknesses, cardiomyocyte area and ventricular mass, without LV dilation, systolic dysfunction, collagen deposition or foetal gene expression. The hypertrophic response to ISO was blunted in mice deficient for B56α.

conclusionThese findings identify B56α as a potential regulator of cardiac structure and function during β-AR stimulation.

Indexed as

IsoproterenolVentricular Function, LeftVentricular RemodelingAdrenergic beta-AgonistsAnimalsCardiomegalyDisease Models, AnimalDobutamineFemaleHeart RateHeterozygoteHomozygoteMaleMice, Inbred C57BLMice, KnockoutMyocytes, CardiacAdrenergic beta-AgonistsDobutamineIsoproterenolPpp2r5a protein, mouseProtein Phosphatase 2Beta-adrenergic receptorsCardiac hypertrophyContractile functionPP2AProtein phosphatases

Identifiers

PMID30203051
PMCPMC6383118
OpenAlexW2891731389

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.